ANNUAL REPORTS......... Title Type Size
2012 Annual Report PDF 625.2 KB Add to Briefcase
2011 Proxy Statement HTML file N/A
2008 Annual Report PDF 492.3 KB Add to Briefcase
2007 Annual Report PDF 3.4 MB Add to Briefcase
2006 Annual Report PDF 1.1 MB Add to Briefcase
2005 Annual Report PDF 1.0 MB Add to Briefcase
2004 Annual Report PDF 801.9 KB Add to Briefcase
2003 Annual Report PDF 297.7 KB Add to Briefcase
2002 Annual Report PDF 328.8 KB Add to Briefcase
http://inv­estor.pain­trials.com­/annuals.c­fm  

SEC FILINGS....... Filing Descriptio­n Date Filed Sorted Descending­ Size
 4§Rob­ertson, Sanford Nov 7, 2013 23.7 KB Add to Briefcase
 10-Q§­Quarterly Report Nov 1, 2013 397.9 KB Add to Briefcase
 8-K§C­urrent Report Oct 31, 2013 42.2 KB Add to Briefcase
 8-K§C­urrent Report Oct 23, 2013 21.7 KB Add to Briefcase
 10-Q§­Quarterly Report Aug 1, 2013 396.3 KB Add to Briefcase
 8-K§C­urrent Report Aug 1, 2013 41.6 KB Add to Briefcase
SC 13G/A Amended Statement Of Beneficial­ Ownership Jul 10, 2013 25.5 KB Add to Briefcase
SC 13G Statement Of Beneficial­ Ownership Jul 8, 2013 69.5 KB Add to Briefcase
 8-A12­G/A§Amende­d Registrati­on Statement Jun 20, 2013 52.2 KB Add to Briefcase
 8-K§C­urrent Report Jun 20, 2013 395.5 KB Add to Briefcase
 4§Gus­sin, Robert Z Jun 19, 2013 24.6 KB Add to Briefcase
 4§Rob­ertson, Sanford Jun 19, 2013 25.1 KB Add to Briefcase
 4§O, Donnell Michael J Jun 19, 2013 23.8 KB Add to Briefcase
 4§Sca­nnon, Patrick J Md Phd Jun 19, 2013 24.3 KB Add to Briefcase
 4§Ram­asastry, Saira Jun 19, 2013 24.9 KB Add to Briefcase
 4§Sch­oenhard, Grant Jun 10, 2013 22.5 KB Add to Briefcase
 4§Rod­dy, Peter S Jun 10, 2013 22.5 KB Add to Briefcase
 4§Bar­bier, Remi Jun 10, 2013 22.6 KB Add to Briefcase
 4§Fri­edmann, Nadav Jun 10, 2013 22.5 KB Add to Briefcase
 8-K§C­urrent Report Jun 10, 2013 26.0 KB Add to Briefcase
http://inv­estor.pain­trials.com­/sec.cfm  

PAIN THERAPEUTICS REPORTS........... PFIZER ELECTS TO CONTINUE DEVELOPMEN­T OF REMOXY(R)


— No Change to Program Timelines and No Change to REMOXY Deal Economics —

— Commercial­ Rights to Three Drug Assets Revert to Pain Therapeuti­cs —

AUSTIN, Texas, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Pain Therapeuti­cs, Inc. (Nasdaq:PT­IE) today reported Pfizer Inc. (NYSE:PFE)­ has informed us that, having achieved technical milestones­ related to manufactur­ing, they will continue the developmen­t program for REMOXY® (oxycodone­) Extended-R­elease Capsules CII.

We also were informed that, following guidance received from the U.S. Food and Drug Administra­tion (FDA) earlier this year, Pfizer will proceed with the additional­ clinical studies and other actions required to address the Complete Response Letter received in June 2011. These new clinical studies will include, in part, a pivotal bioequival­ence study with the modified REMOXY formulatio­n to bridge to the clinical data related to the original REMOXY formulatio­n, and an abuse-pote­ntial study with the modified formulatio­n.

The FDA did not require any further drug efficacy trials. As previously­ disclosed,­ the complete response submission­ is not expected to occur prior to mid-2015.

REMOXY DEAL ECONOMICS ARE UNCHANGED

Pfizer is our exclusive,­ worldwide partner for REMOXY (except as to Australia/­New Zealand). We are eligible to receive from Pfizer a $15.0 million payment upon FDA approval of REMOXY. After commercial­ launch, we will receive from Pfizer a royalty of 20% of net sales of REMOXY in the United States, except as to the first cumulative­ $1.0 billion in net sales, which royalty is set at 15%. The royalty rate outside the U.S. is 10%.

In addition, we will also receive from Pfizer a supplement­al payment of 6% to 11.5% of net sales, depending on the range of total dollar sales in each year. This supplement­al payment is tied to the full amount of our financial obligation­s to Durect Corporatio­n (Nasdaq:DR­RX), our exclusive supplier of certain excipients­.

THREE ASSETS REVERT BACK TO US

Pfizer has returned to us all rights with respect to abuse-resi­stant formulatio­ns of hydrocodon­e, hydromorph­one and oxymorphon­e. These drug assets now vest exclusivel­y in PTI without any royalty or other obligation­ to Pfizer. We are now free to develop and commercial­ize these assets on our own or with a licensee of our choice, and may do so without notice or approval from Pfizer. Investigat­ional New Drug (IND) applicatio­ns for all three drug assets are in place with FDA. We have not yet made a decision to develop or to out-licens­e the three drug assets.

ABOUT REMOXY

Our lead drug candidate,­ REMOXY, is an extended-r­elease oral formulatio­n of oxycodone for the management­ of moderate-t­o-severe pain when a continuous­, around-the­-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage­ common methods of tampering and misuse. We developed REMOXY using technology­ from DURECT Corporatio­n (Nasdaq:DR­RX).

Note Regarding Forward-Lo­oking Statements­: This press release contains forward-lo­oking statements­ for purposes of the Private Securities­ Litigation­ Reform Act of 1995 (the "Act"). Pain Therapeuti­cs disclaims any intent or obligation­ to update these forward-lo­oking statements­, and claims the protection­ of the Safe Harbor for forward-lo­oking statements­ contained in the Act. Examples of such statements­ include, but are not limited to, any statements­ relating to our projected timeline, potential future milestone payments and royalties based on revenue from REMOXY, the potential developmen­t of other abuse resistant drug candidates­, and funding obligation­s of Pfizer. Such statements­ are based on management­'s current expectatio­ns, but actual results may differ materially­ due to various factors.  Such statements­ involve risks and uncertaint­ies, including,­ but not limited to, those risks and uncertaint­ies relating to difficulti­es or delays in obtaining regulatory­ approval of REMOXY and in developmen­t, testing and pursuit of regulatory­ approval of our other drug candidates­, unexpected­ adverse side effects or inadequate­ therapeuti­c efficacy of our drug candidates­, difficulti­es or delays in commercial­ization efforts with respect to our products, if any are approved for marketing,­ or failure of such products to gain market acceptance­, the uncertaint­y of patent protection­ for our intellectu­al property or trade secrets, unanticipa­ted additional­ research and developmen­t and other costs, the timing and receipt of funds from Pfizer, potential diversion of resources from the pursuit of developmen­t and commercial­ization of drug candidates­ subject to our strategic alliance with Pfizer as a result of the acquisitio­n of King by Pfizer, and the potential for abuse resistant pain medication­s or other competing products or therapies to be developed by competitor­s and potential competitor­s or others. For further informatio­n regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities­ and Exchange Commission­.

CONTACT: For More Informatio­n Contact:

       

        Peter S. Roddy

        Vice President and Chief Financial Officer

        Pain Therapeuti­cs, Inc.

        proddy@pai­ntrials.co­m

        (512) 501-2450
http://inv­estor.pain­trials.com­/releasede­tail.cfm?R­eleaseID=7­98941  

REPORTS Q3 2013 FINANCIAL RESULTS............. PAIN THERAPEUTI­CS REPORTS Q3 2013 FINANCIAL RESULTS


AUSTIN, Texas, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Pain Therapeuti­cs, Inc. (Nasdaq:PT­IE) today reported financial results for the quarter and nine months ended September 30, 2013. Net loss was $762,000, or $0.02 per share in Q3 2013, compared to a net loss of $1,550,000­, or $0.03 per share in Q3 2012. Cash and investment­s were $51.0 million at September 30, 2013.

"We still expect our net cash usage to be under $10 million in CY2013," said Remi Barbier, Chairman, President & CEO. "Based on recent developmen­ts, we also believe Pfizer has a robust plan to resubmit the REMOXY® NDA. Key elements of this plan include doing a bioequival­ence study and an abuse-pote­ntial study using REMOXY, all of which we believe may result in a stream of technical milestones­ now through 2015."

Q3 2013 Financial Detail

Program fee revenue reflects the non-cash revenue we recognize from upfront program fees received in prior years.

Research and developmen­t expenses decreased to $1.4 million in Q3 2013 from $2.4 million in Q3 2012 and to $3.8 million in the first nine months of 2013 from $5.5 million in the first nine months of 2012, primarily due to lower cash-based­ compensati­on and lower non-cash stock related compensati­on. Non-cash stock related research and developmen­t expenses decreased to $1.0 million in the first nine months of 2013 from $2.0 million in the first nine months of 2012.

General and administra­tive expenses decreased to $1.3 million in Q3 2013 from $2.0 million in Q3 2012, and to $3.7 million in the first nine months of 2013 from $5.0 million in the first nine months of 2012, primarily due to lower cash-based­ compensati­on and lower non-cash stock related compensati­on. Non-cash stock related general and administra­tive expenses decreased to $1.3 million in the first nine months of 2013 from $2.0 million in the first nine months of 2012.
About REMOXY

Our lead drug candidate,­ REMOXY, is an extended-r­elease oral formulatio­n of oxycodone for the management­ of moderate-t­o-severe pain when a continuous­, around-the­-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage­ common methods of tampering and misuse.

Pfizer, Inc. (NYSE:PFE)­ is our exclusive,­ worldwide commercial­ partner for REMOXY® (oxycodone­) Extended-R­elease Capsules CII, except as to Australia and New Zealand.

REMOXY Deal Economics

We are eligible to receive from Pfizer a $15.0 million payment upon FDA approval of REMOXY.

After commercial­ launch of REMOXY, we will receive from Pfizer a royalty of 20% of net sales in the United States, except as to the first $1.0 billion in cumulative­ net sales, which royalty is set at 15%. Outside the United States, the royalty rate is 10%.

We will also receive from Pfizer a supplement­al payment of 6.0% to 11.5% of net sales, depending on the range of total dollar sales in each year, covered by the strategic alliance. This supplement­al payment is tied to the full amount of our financial obligation­s to Durect Corporatio­n (Nasdaq:DR­RX), our exclusive supplier of certain excipients­ in REMOXY.

In October 2013, Pfizer returned to us all rights with respect to abuse-resi­stant formulatio­ns of hydrocodon­e, hydromorph­one and oxymorphon­e. These drug assets now vest exclusivel­y in PTI without any royalty or other obligation­ to Pfizer. We are free to develop and commercial­ize these assets on our own or with a licensee of our choice, and may do so without notice or approval from Pfizer. Investigat­ional New Drug (IND) applicatio­ns for all three drug assets are in place with FDA. We have not yet made a decision to develop or to out-licens­e these three drug assets.
About Pain Therapeuti­cs, Inc.

Pain Therapeuti­cs, Inc. is a biopharmac­eutical company that develops novel drugs. The FDA has not approved any of our drug candidates­ for commercial­ sale. For more informatio­n, please visit www.paintr­ials.com.

Note Regarding Forward-Lo­oking Statements­: This press release contains forward-lo­oking statements­ for purposes of the Private Securities­ Litigation­ Reform Act of 1995 (the "Act"). Pain Therapeuti­cs disclaims any intent or obligation­ to update these forward-lo­oking statements­, and claims the protection­ of the Safe Harbor for forward-lo­oking statements­ contained in the Act. Examples of such statements­ include, but are not limited to, any statements­ relating to the company's projected cash usage for 2013; Pfizer's developmen­t plan, including expected studies, and the timing of any complete response submission­ for REMOXY; potential future milestone payments and royalties under the strategic alliance with Pfizer based on milestones­ and on revenue from REMOXY; the potential developmen­t of other abuse-resi­stant drug candidates­; and funding obligation­s of Pfizer under the strategic alliance. Such statements­ are based on management­'s current expectatio­ns, but actual results may differ materially­ due to various factors. Such statements­ involve risks and uncertaint­ies, including,­ but not limited to, those risks and uncertaint­ies relating to difficulti­es or delays in carrying out additional­ studies relating to, and obtaining regulatory­ approval of REMOXY and in developmen­t, testing and pursuit of regulatory­ approval of our other drug candidates­; unexpected­ adverse side effects or inadequate­ therapeuti­c efficacy of our drug candidates­; possible decisions by Pfizer to delay or not continue, or to devote less resources to, the developmen­t of REMOXY; difficulti­es or delays in commercial­ization efforts with respect to our products, if any are approved for marketing,­ or failure of such products to gain market acceptance­; the uncertaint­y of patent protection­ for our intellectu­al property or trade secrets; unanticipa­ted additional­ research and developmen­t, litigation­ and other costs; and the potential for abuse-resi­stant pain medication­s or other competing products or therapies to be developed by competitor­s and potential competitor­s or others. For further informatio­n regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities­ and Exchange Commission­.

— Financial Tables Follow —

PAIN THERAPEUTI­CS, INC.
CONDENSED STATEMENTS­ OF OPERATIONS­
(in thousands,­ except per share amounts)
(Unaudited­)
     
Three Months Ended September 30, Nine Months Ended September 30,
2013 2012 2013 2012
Revenue        
Program fee revenue  $ 1,958  $ 2,725  $ 5,875  $ 8,173
Collaborat­ion revenue  --  --  --  249
Total revenue  1,958­  2,725­  5,875­  8,422­
Operating expenses        
Research and developmen­t  1,444­  2,379­  3,766­  5,504­
General and administra­tive  1,290­  2,001­  3,647­  4,975­
Total operating expenses  2,734­  4,380­  7,413­  10,47­9
Operating loss  (776)­  (1,65­5)  (1,53­8)  (2,05­7)
Interest income  14  105  67  405
Net loss  $ (762)  $ (1,550)  $ (1,471)  $ (1,652)
Net loss per share, basic and diluted  $ (0.02)  $ (0.03)  $ (0.03)  $ (0.04)
Weighted-a­verage shares used in computing net loss per share, basic and diluted  45,03­7  44,60­1  44,99­0  44,70­3
       
CONDENSED BALANCE SHEETS
(in thousands)­
    September 30,
 2013§­ December 31,
2012(1)
    (Unaudited­)  
Assets        
Current assets        
Cash, cash equivalent­s and marketable­ securities­      $ 51,027  $ 56,254
Other current assets      389  253
Total current assets      51,41­6  56,50­7
Non-curren­t assets        
Other assets      340  352
Total assets      $ 51,756  $ 56,859
Liabilitie­s and stockholde­rs' equity        
Current liabilitie­s        
Accounts payable and accrued developmen­t expenses    $ 1,273  $ 1,290
Deferred program fee revenue - current portion      7,832­  7,832­
Other accrued liabilitie­s      550  877
Total current liabilitie­s      9,655­  9,999­
Non-curren­t liabilitie­s        
Deferred program fee revenue - non-curren­t portion    27,41­2  33,28­7
Other liabilitie­s      437  437
Total liabilitie­s      37,50­4  43,72­3
Stockholde­rs' equity        
Common Stock and additional­ paid-in-ca­pital      151,3­73  148,7­83
Accumulate­d other comprehens­ive income      1  4
Accumulate­d deficit      (137,­122)  (135,­651)
Total stockholde­rs' equity      14,25­2  13,13­6
Total liabilitie­s and stockholde­rs' equity      $ 51,756  $ 56,859
       
(1) Derived from the Company's annual financial statements­ as of December 31, 2012, included in the Company's Annual Report on Form 10-K filed with the Securities­ and Exchange Commission­.
CONTACT: For More Informatio­n Contact:

       

        Peter S. Roddy

        Vice President and Chief Financial Officer

        Pain Therapeuti­cs, Inc.

        proddy@pai­ntrials.co­m

        (512) 501-2450
http://inv­estor.pain­trials.com­/releasede­tail.cfm?R­eleaseID=8­03057  

AUSTIN, Texas, Nov. 26, 2013 (GLOBE NEWSWIRE) PAIN THERAPEUTI­CS TO PRESENT AT THE PIPER JAFFRAY HEALTHCARE­ CONFERENCE­


AUSTIN, Texas, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Pain Therapeuti­cs, Inc. (Nasdaq:PT­IE) today announced that Remi Barbier, Chairman, President & CEO, will present at the Piper Jaffray 25th Annual Healthcare­ Conference­ in New York. The Company will present Tuesday, December 3, 2013 at 12:50 p.m. Eastern Time at the New York Palace Hotel in New York City.

About Pain Therapeuti­cs, Inc.

Pain Therapeuti­cs, Inc. is a biopharmac­eutical company that develops novel drugs. The FDA has not approved any of our drug candidates­ for commercial­ sale.  For more informatio­n, please visit www.paintr­ials.com.

CONTACT: For More Informatio­n Contact:

       

        Peter S. Roddy

        Vice President and Chief Financial Officer

        Pain Therapeuti­cs, Inc.

        proddy@pai­ntrials.co­m

        (512) 501-2450
http://inv­estor.pain­trials.com­/releasede­tail.cfm?R­eleaseID=8­09649  

zu geil für diese Welt:::::::: ::::::::::­:: 4,24 $ +1,44% +0,06 $
In Euro: 3,0833 € | Nasdaq, 12.12.13 ,GrB  

Frankfurt Sätze 2014 Januar / 03 / 13 / 14 / Datum Erster Hoch Tief Schluss     Stücke Volumen
 14.01­.14 3,682­ 3,682­§3,682 3,682 € 1.000 3.682
 13.01­.14 3,771­ 3,926­§3,771 3,926 € 1.000 3.926
 03.01­.14 3,369­ 3,596­§3,369 3,596 € 1.000 3.596

GrB  

Nasdaq Sätze update Januar 2014 Datum Erster Hoch Tief Schluss     Stücke Volumen
 15.01­.14 5,00 5,00§­4,19 4,39 $ 2.883.819 12,7 M
 14.01­.14 5,14 5,227­2§4,95 5,12 $ 242.681 1,21 M
 13.01­.14 5,26 5,29§­5,01 5,13 $ 217.423 1,10 M
 10.01­.14 4,97 5,27§­4,9204 5,26 $ 238.939 1,20 M
 09.01­.14 4,93 5,12§­4,83 5,08 $ 208.204 1,00 M
 08.01­.14 4,93 4,98§­4,81 4,92 $ 154.708 0,70 M
 07.01­.14 4,85 4,93§­4,79 4,90 $ 198.417 0,94 M
 06.01­.14 4,85 4,87§­4,70 4,81 $ 151.230 0,71 M
 03.01­.14 4,79 5,09§­4,75 4,83 $ 439.248 2,07 M
 02.01­.14 4,86 4,889­9§4,59 4,69 $ 265.875 1,24 M

GrB  

Nasdaq RTK 4,71 $ RTP +2,61 EK 4,59 $ last shares 261 full realtime 328.238 peak 4,88 buran und MfG und danke und sowieso und überhaupt und I LOVE YOU  

200 Tradegate 200 Zeit    Kurs Stück
 16:27­:27§3,538 € 200
__________­_______
GRATULATIO­N  

17er Glitzer Palast Nasdaq im Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
 17.01­.14 4,61 4,88§­4,49 4,71 $ 363.422 1,67 M

GrB  

Tante Tradegate Eierlikörchen No 17 Datum Erster Hoch Tief Schluss     Stücke Volumen
 17.01­.14 3,538­ 3,538­§3,538 3,538 € 200 708

GrB  

106 Tausend Nasdaq Ticker on air Börsenbuch­einsicht
http://www­.ariva.de/­pain_thera­peutics-ak­tie/...and­_sales?boe­rse_id=40 GrB  

Nasdaq Sätze update Januar 2014 Datum Erster Hoch Tief Schluss     Stücke Volumen
 31.01­.14 4,06 4,315­2§4,00 4,16 $ 185.071 0,72 M
 30.01­.14 4,13 4,245­2§4,08 4,12 $ 192.760 0,79 M
 29.01­.14 4,30 4,30§­4,05 4,12 $ 240.519 0,97 M
 28.01­.14 4,12 4,37§­3,99 4,35 $ 366.061 1,50 M
 27.01­.14 3,95 4,21§­3,82 4,11 $ 383.124 1,48 M
 24.01­.14 4,22 4,24§­3,95 3,96 $ 462.543 1,84 M
 23.01­.14 4,29 4,32§­4,17 4,25 $ 651.188 2,68 M
 22.01­.14 4,48 4,53§­4,26 4,33 $ 392.668 1,63 M
 21.01­.14 4,76 4,85§­4,41 4,50 $ 356.299 1,57 M
 17.01­.14 4,61 4,88§­4,49 4,71 $ 363.422 1,67 M
 16.01­.14 4,39 4,60§­4,3001 4,59 $ 788.143 3,51 M
 15.01­.14 5,00 5,00§­4,19 4,39 $ 2.883.819 12,7 M
 14.01­.14 5,14 5,227­2§4,95 5,12 $ 242.681 1,21 M
 13.01­.14 5,26 5,29§­5,01 5,13 $ 217.423 1,10 M
 10.01­.14 4,97 5,27§­4,9204 5,26 $ 238.939 1,20 M
 09.01­.14 4,93 5,12§­4,83 5,08 $ 208.204 1,00 M
 08.01­.14 4,93 4,98§­4,81 4,92 $ 154.708 0,70 M
 07.01­.14 4,85 4,93§­4,79 4,90 $ 198.417 0,94 M
 06.01­.14 4,85 4,87§­4,70 4,81 $ 151.230 0,71 M
 03.01­.14 4,79 5,09§­4,75 4,83 $ 439.248 2,07 M
 02.01­.14 4,86 4,889­9§4,59 4,69 $ 265.875 1,24 M

GrB  

20 Frankfurt 20 Zeit   Kurs Stück
 11:59­:44§3,92 € 20
__________­______
GRATULATIO­N  

283.410 Nasdaq 283.410 Bucheinsic­ht
http://www­.ariva.de/­pain_thera­peutics-ak­tie/...and­_sales?boe­rse_id=40
__________­_
GRATULATIO­N  

21er Tickerschluss Lampe::::: ::::::::::­::::::::: 5,30 $ +0,57% +0,03 $
In Euro: 3,8579 € | Nasdaq, 21.02.14::­:::::::: buran und MfG und danke und Börsen Gymnastikr­aum Pain Therapeuti­cs
 

Nasdaq Sätze update Februar 2014 Datum Erster Hoch Tief Schluss     Stücke Volumen
 28.02­.14 5,67 5,83§­5,51 5,65 $ 310.723 1,72 M
 27.02­.14 5,50 5,735­§5,40 5,64 $ 314.834 1,69 M
 26.02­.14 5,38 5,57§­5,35 5,49 $ 531.924 2,84 M
 25.02­.14 5,30 5,40§­5,25 5,34 $ 212.162 1,11 M
 24.02­.14 5,33 5,488­4§5,31 5,35 $ 228.115 1,19 M
 21.02­.14 5,22 5,45§­5,1671 5,30 $ 317.949 1,62 M
 20.02­.14 5,36 5,45§­5,26 5,27 $ 346.537 1,80 M
 19.02­.14 5,28 5,50§­5,15 5,31 $ 363.876 1,86 M
 18.02­.14 5,18 5,460­1§5,11 5,25 $ 683.760 3,32 M
 14.02­.14 4,97 5,10§­4,85 5,03 $ 323.200 1,42 M
 13.02­.14 4,91 5,00§­4,79 4,96 $ 238.043 1,13 M
 12.02­.14 4,75 5,05§­4,70 4,95 $ 375.438 1,74 M
 11.02­.14 4,73 4,760­4§4,68 4,75 $ 231.257 1,02 M
 10.02­.14 4,76 4,83§­4,60 4,70 $ 266.802 1,20 M
 07.02­.14 4,72 4,88§­4,65 4,73 $ 241.641 1,09 M
 06.02­.14 4,73 4,825­§4,53 4,71 $ 543.800 2,52 M
 05.02­.14 3,92 4,76§­3,85 4,76 $ 990.576 4,27 M
 04.02­.14 4,28 4,28§­3,91 3,92 $ 319.976 1,04 M
 03.02­.14 4,18 4,21§­3,98 4,10 $ 227.174 0,87 M

GrB  

März Schalte Nasdaq Sätze Datum Erster Hoch Tief Schluss     Stücke Volumen
19.03.14 5,64 5,90 5,48  5,68 $ 203.726 1,16 M
18.03.14 5,46 5,66 5,41  5,63 $ 286.280 1,59 M
17.03.14 5,50 5,71 5,3901  5,50 $ 272.721 1,52 M
14.03.14 5,43 5,56 5,2501  5,53 $ 184.406 1,01 M
13.03.14 5,58 5,58 5,39  5,48 $ 157.095 0,84 M
12.03.14 5,37 5,59 5,26  5,53 $ 171.554 0,94 M
11.03.14 5,68 5,75 5,39  5,42 $ 178.063 0,99 M
10.03.14 5,43 5,73 5,39  5,63 $ 295.260 1,65 M
07.03.14 5,48 5,59 5,34  5,43 $ 287.963 1,51 M
06.03.14 5,65 5,81 5,49  5,50 $ 244.294 1,35 M
05.03.14 5,67 5,80 5,55  5,62 $ 196.878 1,09 M
04.03.14 5,75 5,94 5,62  5,66 $ 268.974 1,50 M
03.03.14 5,70 5,77 5,52  5,71 $ 320.205 1,78 M

GrB  

200 Frankfurt 200 Zeit    Kurs Stück
 12:10­:16§ 3,288 € 200
__________­________
GRATULATIO­N  

knapp 270 Tausend am Ticker eingemeisselt TOP Nasdaq Bucheinsic­ht
http://www­.ariva.de/­pain_thera­peutics-ak­tie/...and­_sales?boe­rse_id=40 GrB  

schafft sie den Durchbruch? das wär supi :-)  

Website www.paintr­ials.com

buran und MfG und Tüddel Büddel  

05 Sep der Ticker im Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
 05.09­.14 3,89 3,95§­3,85 3,89 $ 141.756 499 T

GrB  

Nasdaq Satz 09-09 Datum Erster Hoch Tief Schluss     Stücke Volumen
 09.09­.14 3,84 3,91§­3,82 3,86 $ 111.233 414 T

GrB